Algorae Locks in Deal With $1.7B Torrent to Fast-Track Generic Drugs to Market
Algorae secures licence and supply agreement with Torrent Pharmaceuticals for ANZ market
Algorae Pharmaceuticals (ASX: 1AI) has executed a Licence & Supply Agreement with Torrent Pharmaceuticals for two generic prescription molecules targeting Australia and New Zealand. The partnership with Torrent, ranked 5th in the Indian Pharmaceuticals Market with annual revenues of approximately AUD$1.68 billion, marks Algorae’s sixth commercial agreement executed through its wholly owned subsidiary AlgoraeRx Pty Ltd.
The agreement establishes a phased commercialisation structure designed to accelerate time-to-market for established generic molecules while the company continues developing its AI-driven drug discovery pipeline.
Torrent Pharmaceuticals operates within the broader Torrent Group, which generates group revenues of approximately AUD$6.58 billion annually. The licence and supply framework positions Algorae for potential near-term revenue generation through commercialisation of proven molecules whilst maintaining focus on its proprietary AlgoraeOS platform development.
When big ASX news breaks, our subscribers know first
Understanding licence and supply agreements in generic pharmaceuticals
A licence and supply agreement in the pharmaceutical sector is a commercial arrangement where one party manufactures the product whilst the other commercialises it within a specific territory. For small-cap pharmaceutical companies, this structure provides access to ready-made product portfolios without bearing the full development and manufacturing costs typically associated with bringing drugs to market.
Geographic exclusivity under such agreements matters significantly for market access strategy. The ANZ rights granted under this agreement allow Algorae to pursue a focused commercialisation approach in defined markets where it can build distribution channels and regulatory relationships.
This model enables emerging pharmaceutical companies to build revenue streams considerably faster than ground-up drug development timelines typically permit.
Phase 1 and Phase 2 commercialisation pathway
The agreement establishes a two-phase commercialisation structure with distinct regulatory and timeline characteristics:
-
Phase 1 targets products supported by existing regulatory registrations in Australia and/or New Zealand, including cloned registrations where applicable. This pathway enables earlier market entry subject to applicable approvals and launch readiness.
-
Phase 2 addresses products requiring new TGA registrations, supporting a longer-term launch pipeline subject to successful regulatory submissions, approvals and supply arrangements.
The LSA provides a framework for the parties to consider additional molecules from Torrent’s portfolio in future phases. Any additional molecules would be included by mutual agreement and remain subject to regulatory, commercial and strategic considerations. There is no current commitment regarding the number, timing, sequencing or commercial terms of any potential additional molecules beyond the initial two covered under this agreement.
Roles under the agreement
The partnership establishes a clear division of responsibilities between the two parties. Torrent Pharmaceuticals holds responsibility for product development and GMP-compliant manufacturing, leveraging its established production infrastructure.
AlgoraeRx Pty Ltd, Algorae’s wholly owned subsidiary, is expected to lead ANZ commercialisation activities encompassing market access, pricing and reimbursement activities across both territories, alongside sales, distribution and commercialisation execution.
Regulatory pathways and timelines will be determined on a molecule-by-molecule basis, subject to applicable requirements. All commercialisation activities remain subject to relevant approvals, final product planning and product availability.
Commercial terms of the agreement remain confidential, with the company committing to update shareholders on submission timing, anticipated launch windows and expected revenue contribution as the phased commercialisation programme advances.
| Party | Responsibilities |
|---|---|
| Torrent Pharmaceuticals | Product development and GMP-compliant manufacturing |
| AlgoraeRx Pty Ltd | Market access, pricing and reimbursement activities, sales, distribution and commercialisation execution across ANZ (subject to relevant approvals and product availability) |
About the partner: Torrent Pharmaceuticals
Torrent Pharmaceuticals operates as the flagship company of the Torrent Group, generating annual revenues exceeding Rs 11,500 crores (approximately AUD$1.68 billion). Following the JB Pharma acquisition, Torrent is positioned as the 5th largest player in the Indian Pharmaceuticals Market and ranks amongst the Top 5 in several therapeutic segments including Cardiovascular, Gastro Intestinal, Central Nervous System, Pain Management and CosmoDermatology.
The company operates with a specialty focus, deriving approximately 76% of its Indian revenues from chronic and sub-chronic therapies. Torrent maintains presence in over 50 countries and holds the No. 1 ranking amongst Indian pharmaceutical companies in both Brazil and Germany.
Manufacturing and research capabilities include:
- 8 manufacturing facilities, of which 5 hold USFDA approval
- State-of-the-art R&D infrastructure employing approximately 750+ scientists
- Significant ongoing investment in R&D capabilities supporting growth in domestic and overseas markets
The partnership with a manufacturer possessing multiple USFDA-approved facilities and established global regulatory track record de-risks supply chain execution for Algorae’s commercialisation objectives across the ANZ territories.
The next major ASX story will hit our subscribers first
Strategic fit with Algorae’s commercial and R&D objectives
This agreement positions within Algorae’s broader dual-track strategy, which balances commercial agreements supporting revenue generation alongside AI-driven R&D programmes via AlgoraeOS. Through AlgoraeRx Pty Ltd, the company has now executed six commercial agreements designed to complement its research and development programmes whilst building potential revenue streams.
The licence and supply framework with Torrent Pharmaceuticals supports a potential revenue pathway independent of the company’s core AI platform development timeline. Algorae’s proprietary AlgoraeOS continues progressing drug synergy discovery programmes targeting unmet medical needs, applying machine learning and deep neural networks to identify therapeutic combinations.
The company continues to pursue additional commercial opportunities beyond the current six executed agreements. Shareholders will receive updates on submission timing, anticipated launch windows and expected revenue contribution as the phased commercialisation programme advances, in accordance with the company’s continuous disclosure obligations under ASX Listing Rules.
Wondering How Algorae Plans to Balance Commercial Revenue with AI-Driven Drug Discovery?
This partnership with Torrent Pharmaceuticals represents Algorae’s sixth commercial agreement, establishing a phased pathway to market for generic molecules whilst the company advances its proprietary AlgoraeOS platform. The dual-track strategy aims to generate near-term revenue streams alongside longer-term AI-driven innovation.
To explore Algorae’s full commercial pipeline and AlgoraeOS development programme, visit the Algorae investor centre for detailed updates on regulatory submissions, anticipated launch timelines and the company’s expanding portfolio of strategic partnerships.